Bioengineered blood vessels for hemodialysis access successfully supported blood flow and evolved into native-like blood vessels in patients with end-stage renal disease (ESRD) participating in 2 phase 2 trials, according to new findings published in Science Translational Medicine. The investigational human acellular vessels (HAVs), developed by Humacyte Inc, are also in phase 2 trials for peripheral arterial disease and vascular trauma.
Abbasi J. Off-the-Shelf Bioengineered Blood Vessels Tested in Trials. JAMA. 2019;321(18):1759. doi:10.1001/jama.2019.5806
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: